COSCIENS Biopharma Inc (CSCI): Analyst Median Target

Corporate company logo of Aeterna Zentaris (CSCI)

The COSCIENS Biopharma Inc. (CSCI) price chart on the GURU.Markets platform is based on the success of the Canadian firm, which holds exclusive distribution rights for pharmaceuticals in Latin America and Canada. The current indicator is 59.80. The business relies on outsourcing production and testing to minimize capital expenditures. Stability is maintained through diversified delivery channels and the stockpiling of raw materials for endocrine drugs.

CSCI COSCIENS Biopharma: Analyst Consensus Forecast in the range 08/10/2024 - 09/14/2025

Metric breakdowns and analytics for Aeterna Zentaris (CSCI)

- market price and analyst price targets:
Stock Quotes cosciensbio.com|CSCI - Price Target Chart
- stock exchange capitalization data:
Market Capitalization Aeterna Zentaris|CSCI - Enterprise Value
- company book value details:
Accounting Value per Share COSCIENS Biopharma|CSCI - Book Capitalization|Market Capitalization to Book Value cosciensbio.com|CSCI - Aggregate Company Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient COSCIENS Biopharma Inc.|CSCI - Long-Term Debt to Equity|Current Liabilities to Equity COSCIENS Bio|CSCI - Company Aggregate Debts|Debts to Book Value Aeterna Zentaris|CSCI - Company Long-Term Debts|Company Current Liabilities COSCIENS Biopharma|Interim Coverage Ratio cosciensbio.com
- business earnings and investment ratios data:
CSCI - Net Profit|Projected Future Earnings COSCIENS Biopharma Inc.|CSCI - Price to Earnings Ratio|Future Price to Earnings COSCIENS Biopharma Inc|CSCI - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Aeterna Zentaris|CSCI - Operating profit before deduction of amortization|Earnings per one share for the last 12 months COSCIENS Biopharma|CSCI - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months cosciensbio.com|CSCI - Earnings growth in current year|Projected earnings per share growth rate for next year COSCIENS Biopharma Inc.
General company analysis:CSCI - cosciensbio.com
Core merchandise of COSCIENS Biopharma Inc

To minimize the risk of overpaying for an asset, it is critical to note that the consensus price target aggregates institutional analyst estimates, reflecting the impact of Fed rates on fair value. In the case of COSCIENS Biopharma Inc. (CSCI), growth potential is embedded in the scalability of its endocrinology drugs, where the success of a single molecule enables global expansion, confirming the fundamental resilience of the business through the dynamics of this indicator.

Competing companies

Consensus Target vrtx.com VRTX|Price Target Chart Alnylam ALNY|Analyst Median Target Insmed Inc. (INSM)|United Therapeutics Corp. - Analyst Consensus Forecast|BioMarin Corp (BMRN) - Consensus Target|BBIO: Analyst Consensus Forecast|BGM - Analyst Median Target|Price Target Chart Cogent Biosciences, Inc.|Xeris Biopharma Holdings, Inc. (XERS) - Analyst Median Target|Price Target Chart Keros Pharma (KROS)|ARCT: Forecast Levels Chart|Analyst Consensus Forecast ETON (Eton Pharmaceuticals)|kamada.com (KMDA) - Average Forecast Price|Fulcrum Therapeutics, Inc. - Analyst Consensus Forecast|Abeona Therapeutics (ABEO) - Consensus Target|MREO: Analyst Consensus Forecast|PLX - Analyst Median Target|PLRX (Pliant Therapeutics Inc) - Analyst Consensus Forecast|Analyst Consensus Forecast Applied Therapeutics Inc.|Price Target Chart Rein Therapeutics (RNTX)|Price Target Chart GELS (gelteq.com)|Analyst Consensus Forecast AYTU (Aytu BioPharma)|Analyst Median Target Chemomab Therapeutics Ltd (CMMB)|SRXH: Consensus Target|Forecast Levels Chart PLRZ|AEZS: Analyst Consensus Forecast|Average Forecast Price Cyclo Therapeutics Inc. (CYTH)|INZY (Inozyme Pharma Inc.) - Analyst Consensus Forecast|Broker Consensus Forecast RPHM (Reneo Pharmaceuticals, Inc)